REGIS HEALTHCARE LIMITED (REG)
Share Price Analysis and Chart

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

24/02/2026

1

Buy

$8.50

26.30%

First half results from Regis Healthcare were better than Ord Minnett expected as the business executes on room pricing initiatives. Revenue rose 18%, supported by occupancy and revenue per bed day.

The company has reiterated FY26 EBITDA guidance of $130-135m and with 52% delivered in the first half, the broker considers the business well-positioned. Buy rating and $8.50 target unchanged.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 17.30 cents and EPS of 18.10 cents.
Ord Minnett forecasts a full year FY27 dividend of 24.30 cents and EPS of 24.20 cents.

04/03/2026

2

Overweight

$8.50

26.30%

Regis Healthcare defied recent share price weakness by delivering an impressive 1H26 result, Jarden suggests, that beat revenue estimates by 5.8%. Similarly, earnings rose 3.7% year on year, more than offsetting the funding shortfall announced in October.

The highlight of the result was net refundable accommodation deposit (RAD) inflows which brings the RAD liability balance to $2.2bn, which sets Regis up well for the 2% RAD retention that commenced 1 November 2025, Jarden notes.

The broker's FY26 earnings forecast remains unchanged but ahead of the $130m-135m guidance range, which Regis now expects will come in at the top end. Target rises to $8.50 from $8.30, Overweight retained.

FORECAST
Jarden forecasts a full year FY26 dividend of 18.00 cents and EPS of 19.00 cents.
Jarden forecasts a full year FY27 dividend of 23.20 cents and EPS of 26.60 cents.